Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL

ARCTIC was a multicenter, randomized-controlled, open, phase IIB non-inferiority trial in previously untreated chronic lymphocytic leukemia (CLL). Conventional frontline therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). The trial hypothesized that including mitoxantrone w...

Full description

Saved in:

Bibliographic Details
Published in:	Leukemia Vol. 31; no. 11; pp. 2416 - 2425
Main Authors:	Howard, D R, Munir, T, McParland, L, Rawstron, A C, Milligan, D, Schuh, A, Hockaday, A, Allsup, D J, Marshall, S, Duncombe, A S, O'Dwyer, J L, Smith, A F, Longo, R, Varghese, A, Hillmen, P
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01-11-2017 Nature Publishing Group
Subjects:	631/67/1990/283/1895 692/308/2779/109/1941 692/308/2779/777 692/700/1750 692/700/565/1436/99 Adult Aged Aged, 80 and over Analysis Antineoplastic Agents - adverse effects Antineoplastic Agents - economics Antineoplastic Agents - therapeutic use Cancer Research Chemotherapy Chronic lymphocytic leukemia Clinical trials Confidence intervals Cost analysis Costs and Cost Analysis Critical Care Medicine Cyclophosphamide Diseases Dosage and administration Dose-Response Relationship, Drug Drug therapy Female Fludarabine Hematology Humans Immunotherapy Intensive Internal Medicine Intravenous administration Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphatic leukemia Lymphocytic leukemia Male Medicine Medicine & Public Health Middle Aged Minimal residual disease Mitoxantrone Monoclonal antibodies Oncology original-article Patients Pharmaceutical industry Polar environments Product development Public relations executives Randomization Remission Rituximab Rituximab - adverse effects Rituximab - economics Rituximab - therapeutic use Survival Survival Analysis Targeted cancer therapy Toxicity Treatment outcome Arctic United Kingdom
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!